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Abstract
Acute myeloid leukemia (AML) is a disease predominantly of older
adults. Treatment of AML in the elderly is complicated not only by
comorbidities but also by the high prevalence of poor prognosis
markers. Thirty-one consecutive unselected patients with AML older
than 60 years (representing 33% of all AML cases diagnosed at our
institution during the same period) were followed over a period of 5
years (1997-2002). A high incidence of AML with multilineage
dysplasia (45%) and no favorable cytogenetic abnormalities but 62%
intermediate and 38% unfavorable karyotypes were found. Sixteen
patients (52%) were selected for induction of intensive cytotoxic
treatment and complete remission was achieved only by some of these
intensively treated patients (7 of 16). Of these, 3 remained alive
without disease (median: 11 months), 1 patient died shortly after
complete remission, and 3 patients relapsed and died from refractory
disease. Only 1 patient that was refractory to intensive cytotoxic
treatment remained alive with disease under supportive care. Fifteen
patients (48%) were managed with palliative/supportive care: 7 re-
ceived palliative treatment and supportive care, 8 received supportive
care only, and 4 patients remained alive with disease under supportive
care (median: 9 months). Mortality rate was 74% and overall survival
at two years was 12%. To the best of our knowledge, there is no
previous report regarding elderly patients with AML in Brazilian
subsets. The present data are similar to previously reported studies
showing that elderly AML patients are not only older but also biologi-
cally distinct from younger AML patients, particularly in terms of the
high incidence of poor prognostic karyotypes and resistance to therapy.
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Introduction
Acute myeloid leukemia (AML) is pre-
dominantly a disease of older adults, with
more than 50% of cases occurring over 60
years of age (1). AML in the elderly is asso-
ciated with several biological and clinical
characteristics such as a high frequency of
blast cells with multidrug resistance glyco-
protein (MDR1) expression and a particu-
larly high incidence of poor prognostic karyo-
types. In addition, treatment of AML in older
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adults is limited by comorbidities that are
frequent in this clinical setting (1). These
features underlie the poorer outcome of these
cases compared with younger patients (2).
However, prospective randomized stud-
ies clearly demonstrate that elderly patients
benefit from more intensive induction thera-
py and particularly from full-dose applica-
tion of anthracyclines and cytarabine (2,3).
To the best of our knowledge, there are
no previous descriptions of the clinical and
cytogenetic features of AML in an elderly
Brazilian population. Since Brazilian patients
differ in ethnic background, endemic infec-
tious diseases, socioeconomic aspects and
medical support from North American or
European patients, perhaps they need more
specific approaches. Thus, we intended to
evaluate the clinical and cytogenetic charac-
teristics as well as the response to chemo-
therapy of an unselected group of Brazilian
patients with AML older than 60 years ad-
mitted to a single institution over a period of
5 years (1997-2002).
Patients and Methods
Patients
Ninety-two adult patients with AML were
diagnosed at Hospital São Paulo (UNIFESP/
EPM) from January 1, 1997 to March 31,
2002, 31 (33%) of them being older than 60
years.
The AML diagnosis was defined in the
presence of at least 20% blasts in bone mar-
row samples and patients were classified
according to the new WHO classification
(4). Being a retrospective study, no informed
consent or approval of therapeutic measures
was necessary by the Hospital Ethics Com-
mittee.
Immunophenotype
Immunophenotypic characterization of
blast cells was performed using a panel of
monoclonal antibodies with triple staining
as previously described (5). Data acquisition
and analysis were performed using a
FACScalibur flow cytometer (Beckton Dick-
inson Immunocytometry Systems, San Jose,
CA, USA) and the Cell quest software.
Cytogenetics
The karyotype was studied in bone mar-
row samples submitted to two short-term
cultures with RPMI medium, 20% fetal calf
serum, 1% L-glutamine and 1% antibiotics
without mitogens (6). At least 15-20 G-
banded metaphases were analyzed and ab-
normalities were described according to
ISCN (1995) recommendations (7).
Treatment schedule
Patients were treated according to their
age, performance status by the Karnofsky
index, and comorbidities. Patients younger
than 75 years with a Karnofsky index >75%
and no major comorbidities (such as kidney
or cardiac failure) were considered for inten-
sive cytotoxic treatment. Patients who did
not meet these criteria were considered for
supportive/palliative care.
The intensive cytotoxic induction proto-
col consisted of cytarabine, 200 mg/m2 per
day on days 1-7, plus daunorubicin, 45 mg/
m2 per day on days 1-3, or idarubicin, 12 mg/
m2 per day, on days 1-3. Complete remission
was defined according to criteria reported by
Cheson et al. (8), <5% bone marrow blast
cells and recovery of hematological param-
eters. When complete remission was not
achieved, a second course of induction thera-
py was tried with mitoxantrone, 10 mg/m2
per day on days 1-5, etoposide, 100 mg/m2
per day on days 1-5, and cytarabine, 200
mg/m2 per day on days 1-7. After complete
remission achievement, consolidation thera-
py was identical to induction therapy.
Palliative treatment consisted of mono-
therapy with hydroxyurea, 500-1500 mg/day,
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when white blood cell count >20 x 109/l,
while supportive care was based on transfu-
sional therapy, antibiotic prophylaxis or an-
tibiotic therapy when needed.
Statistical analysis
The differences in treatment responses
between the two groups, such as complete
remission and survival, were evaluated by
the Mann-Whitney test and the Kaplan-Meier
method, with the level of significance set at
P<0.05.
Results
Thirty-one (33%) patients older than 60
years were diagnosed during this 5-year pe-
riod at Hospital São Paulo (UNIFESP/EPM).
Age ranged from 61 to 85 years (median age
= 70 years) and there was a preponderance
of females (1.6 female:1 male). At diagno-
sis, median hemoglobin levels ranged from
4.1 to 11.7 g/dl (median = 6.7 g/dl) and white
blood cell count from 0.9 to 112 x 109/l
(median = 8.6 x 109/l).
According to the WHO classification, 14
patients (45%) had AML with multilineage
dysplasia, 5 AML with maturation, 3 AML
without maturation, 3 acute myelomonocytic
leukemia, 2 monocytic leukemia, 1 mono-
blastic leukemia, 2 megakaryoblastic leuke-
mia, and 1 AML developed after myelodys-
plastic syndrome therapy with an alkylating
agent for vaginal lymphoma (Table 1).
A search for cytogenetic abnormalities
was conducted in 29 patients and karyotype
results were successful in 21 cases (72.4%)
(Table 1). No patient presented favorable
cytogenetic abnormalities but intermediate
or adverse prognosis karyotypes (9,10). Pa-
tients with t(9;22), -7,t(3;3), del(7q), and
complex karyotype were described elsewhere
(11).
We observed that adverse cytogenetic
abnormalities were associated with a lower
complete remission rate (3 of 6, 50%) as
Table 2. Patient distribution according to type of therapy and clinical data.
Intensive cytotoxic Supportive/palliative Total
N (patients) 16 15 31
Age (years) 61-74 (65) 63-85 (75) 61-85 (70)
Sex (female/male) 9/7 10/5 19/12
Complete remission 43% 0% 43%
Mortality 12 (75%) 11 (73%) 23 (74%)
Alive without disease 3 0 3
Alive with disease 1 4 5
compared with patients with intermediate
findings (3 of 4, 75%), although the differ-
ence was not statistically significant.
Sixteen patients were scheduled for in-
tensive cytotoxic treatment, 7 patients re-
ceived palliative treatment with supportive
care, and 8 received supportive care only
(Table 2).
Intensively treated group
Of 16 treated patients, 9 did not achieve
complete remission. Of these, 8 died from
refractory disease (after 0.5 to 6 months) and
1 refractory patient remained alive with dis-
ease under supportive care. Only 7 of 16
Table 1. Cytogenetic findings of 21 unselected elderly patients with acute myeloid
leukemia and prognosis determined according to Grimwade et al. (10).
Prognosis group N G-banding karyotype
stratification
Favorable 0 None
Intermediate (62%) 13 Normal (46,XX or 46,XY) 12 patients
48,XY,+8,+22[14]/46,XY[1]
Unfavorable (38%) 8 47,XX,+11[5]/46,XX[10]
46,XX,add(21)(q22)[15]
45,XY,t(3;?)(q26;?),-7,-12,+mar[15]
46,XX,t(3;3)(q21;q26)[20]
47,XX,del(7)(q31),+8[3]/46,XX[5]
47,XX,+8[1]/47,XX,del(5)(q34),del(7)(q22),+8[4]
45,XY,-7[16]/46,XY[4]
46,XX,t(9;22)(q34.1;q11.2)[15]
Note: Patients with t(9;22); -7,t(3;3), del(7q), and complex karyotype were described
elsewhere (11). The numbers within square brackets are the metaphase number
analyzed as internationally standardized (7).
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(43%) intensively treated patients achieved
complete remission, 6 with a first course of
induction therapy and 1 after the second
course (cytarabine, etoposide and mitoxan-
trone). Of these 7 patients, 1 died due to
infectious complications shortly after com-
plete remission achievement (less than one
month) and 3 relapsed and died from refrac-
tory disease (median = 16 months after com-
plete remission). Only 3 patients remained
alive without any clinical or hematological
evidence of disease (continuous complete
remission) for 26, 11 and 8 months, respec-
tively (median = 11 months). The mortality
rate for this group was 75% (12 of 16)
(Figure 1).
Supportive treatment/palliative care
Among 15 patients who underwent sup-
portive treatment and/or palliative care, 11
died from infectious or bleeding complica-
tions. Four patients remained alive with dis-
ease under supportive care (median follow-
up = 9 months). The mortality rate for this
group was 73% (11 of 15).
General mortality and survival
Overall mortality rate was 74% and mean
overall survival was 2 months (0-50). Over-
all survival was 22% at one year and 9% at
two years. Mortality rate (75 vs 73%), over-
all survival at one year (25 vs 20%) and at
two years (1 vs 6%) did not differ between
the intensively treated group and the pallia-
tive/supportive care group (P>0.05).
Discussion
The present study was undertaken to ana-
lyze different aspects of 31 consecutive eld-
erly patients with AML. Some forms of AML
that are associated with poor prognosis at
any age are more prevalent in older adults (1).
We also found a high incidence of AML
with multilineage dysplasia (45%) and one
case of AML developed after myelodysplas-
tic syndrome therapy.
Therefore, no favorable cytogenetic ab-
normalities were found in the present study
but, according to others, 62% of intermedi-
ate prognosis (9,10) and a higher frequency
(38%) of unfavorable findings (9,10). We
observed that adverse cytogenetic abnormali-
ties were associated with a lower complete
remission rate (50%) compared with patients
with intermediate findings (75%), although
the difference was not statistically signifi-
cant. Perhaps this difference could be de-
tected in larger series.
Therapeutic results for patients older than
60 years admitted to clinical trials of inten-
sive chemotherapy are largely unsatisfac-
tory, with a median relapse-free survival
usually lower than 12 months (12,13). Cur-
rently, complete remission rates achieved
with conventional chemotherapy range from
40 to 65% according to some investigators
(13) and as shown here. In fact, complete
remission was achieved only by some of the
intensively treated patients (43%). Further
improvement of complete remission rate and
duration will depend equally on the optimi-
zation of supportive care measures and the
introduction of more effective therapeutic
modalities (3).
The optimal management of AML in eld-
Figure 1. Overall survival of elderly Brazilian myeloid leukemia patients. The curves were
constructed according to the Kaplan-Meier estimate.
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erly patients remains a controversial issue.
Complete remission rates after conventional
induction chemotherapy progressively de-
crease after the age of 60. This is explained
by host-related factors and by differences in
the biology of leukemia (13). The incidence
of adverse prognostic factors (trilineage
myelodysplasia, unfavorable karyotype,
MDR1-positive immunophenotype) is higher
in elderly patients (1,13,14).
The two main strategies for improving
outcomes in older adults with AML are to
develop effective chemotherapeutic regimens
with improved tolerability and to reduce drug
resistance. But a satisfactory balance be-
tween efficacy and toxicity has not yet been
achieved (1). Also, the use of growth factors
to promote hematopoietic recovery has yet
to yield consistent reductions in treatment-
related morbidity or mortality (15).
Drug resistance can be modified by in-
hibiting drug efflux mechanisms (cyclo-
sporine and valspodar) or by increasing sen-
sitivity to cytotoxic agents, but these strate-
gies have not yet been shown to significantly
affect outcomes (16,17).
Novel approaches including antibody-
targeted chemotherapy (gentuzumab ozoga-
micin) may have the potential to improve
prognosis for older adults with AML (18-20)
but are still in the clinical trial stage.
Application of prognostic factors may
permit to separate patients who would actu-
ally benefit from aggressive chemotherapy
from those who should be offered attenu-
ated/palliative treatments or enrolled in ex-
perimental trials of new drugs or biological/
immunological treatments (14).
Since 9.3% of the Brazilian population
(21) living in São Paulo belong to the elderly
segment and since life expectancy is 68.55
years in this region, it was interesting to find
that 33% of adult patients with AML admit-
ted to Hospital São Paulo were over 60 years
of age, as compared to the 50-55% rate
reported in other international series (1).
This raises many questions such as whether
the elderly do not have proper access to
health care, or whether comorbidities or so-
cial aspects prevent the ideal diagnostic pro-
cedures, among other causes. Also, the fe-
male to male ratio in this age group in São
Paulo is 1.17:1 (21) and in the elderly leuke-
mia patients a 1.6:1 ratio was observed, an
unexpected finding (12,22).
The present results are similar to those
reported in foreign studies, showing that this
specific group of patients with AML is not
only older but also biologically distinct. We
could notice that even in a group of low
socioeconomic profile in a developing coun-
try intensive treatment programs are appli-
cable to the elderly with AML and that pro-
longed disease-free survival is possible for
some, although it is clear that efforts are
needed to pursue early diagnosis, prompt
assistance and care, and to define specific
groups tailored for new promising therapies.
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